Prosecution Insights
Last updated: October 04, 2026
Application No. 18/279,903

PROCESS FOR PREPARING A MELAMINE CONDENSATION PRODUCT

Final Rejection §112
Filed
Sep 01, 2023
Priority
Mar 04, 2021 — EU 21160664.5 +1 more
Examiner
AULAKH, CHARANJIT
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BASF SE
OA Round
2 (Final)
81%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
66%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
1441 granted / 1787 resolved
+20.6% vs TC avg
Minimal -14% lift
Without
With
+-14.5%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
61 currently pending
Career history
1817
Total Applications
across all art units

Statute-Specific Performance

§101
3.3%
-36.7% vs TC avg
§103
15.0%
-25.0% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
43.5%
+3.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1787 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . According to paper filed on Aug. 17, 2026, the applicants have amended claims 16, 26, 27, 29 and 30. Claims 16-30 are pending in the application. Claims 28 and 30 are withdrawn from further consideration as being directed to non-elected subject matter. Response to Arguments Applicants’ arguments filed Aug. 17, 2026 have been fully considered but they are not persuasive regarding prior art rejection of claims 26, 27 and 29. The applicants have amended claims to overcome indefiniteness rejection and obviousness rejections. The examiner agrees with applicants’ arguments regarding both obviousness rejections. Regarding prior art rejection over Jurgen’s reference, the examiner does not agree with applicant’s arguments on pages 5-6 that this reference does not anticipate the instant claims. As stated clearly in the last office action, claims are directed to product by process. Therefore, the process is irrelevant. The examiner also does not agree with applicants’ arguments regarding prior art rejection of claim 29 over Heinen’s reference. Claim 1 is directed to fire retardant composition comprising melamine condensation products (melem and melan) containing .01% melamine and 0.1% higher condensation products. Therefore, claim 1 of Heinen does anticipate the instant claim 29. Conclusion Rejection of claims 26 and 27 under 35 U.S.C. 102(a) (1) over Jurgen’s reference is maintained. Rejection of claim 29 under 35 U.S.C. 102(a) (1) over Heinen’s reference is maintained. NEW GROUNDS OF REJECTION Claim Rejections - 35 USC § 112 7. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 16-26 and 29 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. There is no written description for preparing melamine condensation product represented by melam or its salt. The only written description is for preparing melamine condensation product represented by melem or its salt (see examples 1-2 and 4-7). IMPROPER MARKUSH GROUP Claims 16-26 and 29 rejected on the basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). A Markush grouping is proper if the alternatives defined by the Markush group (i.e., alternatives from which a selection is to be made in the context of a combination or process, or alternative chemical compounds as a whole) share a “single structural similarity” and a common use. A Markush grouping meets these requirements in two situations. First, a Markush grouping is proper if the alternatives are all members of the same recognized physical or chemical class or the same art-recognized class, and are disclosed in the specification or known in the art to be functionally equivalent and have a common use. Second, where a Markush grouping describes alternative chemical compounds, whether by words or chemical formulas, and the alternatives do not belong to a recognized class as set forth above, the members of the Markush grouping may be considered to share a “single structural similarity” and common use where the alternatives share both a substantial structural feature and a common use that flows from the substantial structural feature. See MPEP § 2117. The Markush grouping of claims 16-26 and 29 is improper because the alternatives defined by the Markush grouping do not share both a single structural similarity and a common use for the following reasons: There is no common structure core present between melamine condensation products, melam, melem and melon. To overcome this rejection, Applicant may set forth each alternative (or grouping of patentably indistinct alternatives) within an improper Markush grouping in a series of independent or dependent claims and/or present convincing arguments that the group members recited in the alternative within a single claim in fact share a single structural similarity as well as a common use. Applicants’ amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARANJIT AULAKH whose telephone number is (571)272-0678. The examiner can normally be reached Monday-Friday 7:00-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARANJIT AULAKH/ Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Sep 01, 2023
Application Filed
Feb 27, 2026
Examiner Interview (Telephonic)
Mar 18, 2026
Non-Final Rejection mailed — §112
Jun 11, 2026
Response after Non-Final Action
Jun 11, 2026
Response Filed
Aug 17, 2026
Response Filed
Sep 23, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747234
KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
3y 5m to grant Granted Sep 29, 2026
Patent 12747263
ORALLY ACTIVE LEUKEMIA INHIBITORY FACTOR (LIF) ANTAGONISTS FOR THE TREATMENT OF CANCER
3y 2m to grant Granted Sep 29, 2026
Patent 12741948
BENZOTHIAZOLE AND QUINOLINE DERIVATIVES AND THEIR USE
3y 6m to grant Granted Sep 22, 2026
Patent 12740987
SOLUBLE PHARMACEUTICAL COMPOSITIONS COMPRISING SALTS OF DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND
2y 8m to grant Granted Sep 22, 2026
Patent 12735421
PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
3y 1m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
81%
Grant Probability
66%
With Interview (-14.5%)
2y 0m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1787 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month